228 related articles for article (PubMed ID: 29701129)
1. Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.
Bergmeijer TO; Vos GJ; Claassens DM; Janssen PW; Harms R; der Heide RV; Asselbergs FW; Ten Berg JM; Deneer VH
Pharmacogenomics; 2018 May; 19(7):621-628. PubMed ID: 29701129
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
Bergmeijer TO; Janssen PW; Schipper JC; Qaderdan K; Ishak M; Ruitenbeek RS; Asselbergs FW; van 't Hof AW; Dewilde WJ; Spanó F; Herrman JP; Kelder JC; Postma MJ; de Boer A; Deneer VH; ten Berg JM
Am Heart J; 2014 Jul; 168(1):16-22.e1. PubMed ID: 24952855
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes and Sustainability of Using
Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
[TBL] [Abstract][Full Text] [Related]
4. Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients.
Black RM; Williams AK; Ratner L; Crona DJ; Wiltshire T; Weck KE; Stouffer GA; Lee CR
Pharmacogenomics; 2020 May; 21(7):431-441. PubMed ID: 32343201
[No Abstract] [Full Text] [Related]
5. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
6. Prospective
Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.
Klein MD; Lee CR; Stouffer GA
Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231
[TBL] [Abstract][Full Text] [Related]
8. Tailored Adjunctive Cilostazol Therapy Based on CYP2C19 Genotyping in Patients With Acute Myocardial Infarction - The CALDERA-GENE Study.
Kaikita K; Yoshimura H; Ishii M; Kudoh T; Yamada Y; Yamamoto E; Izumiya Y; Kojima S; Shimomura H; Tsunoda R; Matsui K; Ogawa H; Tsujita K;
Circ J; 2018 May; 82(6):1517-1525. PubMed ID: 29743380
[TBL] [Abstract][Full Text] [Related]
9. The effect of
Tan K; Lian Z; Shi Y; Wang X; Yu H; Li M; Tian J; Ge Y
Per Med; 2019 Jul; 16(4):301-312. PubMed ID: 31322488
[No Abstract] [Full Text] [Related]
10. Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773).
Kołtowski Ł; Aradi D; Huczek Z; Tomaniak M; Sibbing D; Filipiak KJ; Kochman J; Balsam P; Opolski G
Kardiol Pol; 2016; 74(4):372-9. PubMed ID: 26365936
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.
Mohammad AM; Al-Allawi NAS
J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy.
Wirth F; Zahra G; Xuereb RG; Barbara C; Fenech A; Azzopardi LM
Int J Clin Pharm; 2016 Apr; 38(2):414-20. PubMed ID: 26980150
[TBL] [Abstract][Full Text] [Related]
13. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.
Cavallari LH
Expert Rev Cardiovasc Ther; 2017 Aug; 15(8):581-589. PubMed ID: 28699807
[TBL] [Abstract][Full Text] [Related]
14. Validation of the Spartan RXCYP2C19 Genotyping Assay Utilizing Blood Samples.
Davis BH; DeFrank G; Limdi NA; Harada S
Clin Transl Sci; 2020 Mar; 13(2):260-264. PubMed ID: 31664775
[TBL] [Abstract][Full Text] [Related]
15. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
16. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Cavallari LH; Franchi F; Rollini F; Been L; Rivas A; Agarwal M; Smith DM; Newsom K; Gong Y; Elsey AR; Starostik P; Johnson JA; Angiolillo DJ
J Transl Med; 2018 Apr; 16(1):92. PubMed ID: 29642909
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.
So DY; Wells GA; McPherson R; Labinaz M; Le May MR; Glover C; Dick AJ; Froeschl M; Marquis JF; Gollob MH; Tran L; Bernick J; Hibbert B; Roberts JD
Pharmacogenomics J; 2016 Feb; 16(1):71-8. PubMed ID: 25850030
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Novkovic M; Matic D; Kusic-Tisma J; Antonijevic N; Radojkovic D; Rakicevic L
Eur J Clin Pharmacol; 2018 Apr; 74(4):443-451. PubMed ID: 29260275
[TBL] [Abstract][Full Text] [Related]
20. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
